We are live on ! Find out more
OCSAW

Oculis Holding AG Warrants

1 day
5 days
1 month
3 months
6 months
Year to date
1 year
5 years
10 years
 

About: Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Employees: 60

0
Funds holding %
of 8,128 funds
Positive news %
Price charts implemented using Lightweight Charts™